Technical Analysis for PTLA - Portola Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 39.99 0.88% 0.35
PTLA closed up 0.88 percent on Friday, April 28, 2017, on 3 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: May 4

Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical PTLA trend table...

Date Alert Name Type % Chg
Apr 27 Stochastic Reached Overbought Other 0.88%
Apr 26 Bearish Engulfing Bearish 3.15%
Apr 21 NR7 Range Contraction 4.69%
Apr 21 Narrow Range Bar Range Contraction 4.69%
Apr 21 Bollinger Band Squeeze Range Contraction 4.69%
Apr 20 Bollinger Band Squeeze Range Contraction 4.63%
Apr 19 Shooting Star Candlestick Bearish 5.07%
Apr 19 Bollinger Band Squeeze Range Contraction 5.07%
Apr 18 NR7 Range Contraction 5.54%
Apr 18 NR7-2 Range Contraction 5.54%

Older signals for PTLA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
Portola Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of thrombosis, other hematologic disorders, and inflammation. Its development products include Betrixaban, an oral once-daily inhibitor of Factor Xa, which is in Phase III development trials for the treatment of venous thromboembolism prophylaxis in acute medically ill patients; and PRT4445, a recombinant protein that is in Phase II trials to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. The company’s products under development also comprise PRT2070, which is in Phase I/II studies to treat B-cell hematologic cancers; and PRT2607 that is in Phase I clinical trials for inflammatory disorders. It has a license and collaboration agreement with Biogen Idec Inc. for the development and commercialization of its clinical-stage product candidates PRT2607; license and collaboration agreement with Aciex Therapeutics, Inc. to co-develop and co-commercialize PRT2070 and related compounds for nonsystemic indications; and an agreement with Astellas Pharma, Inc. to research, develop, and commercialize Syk inhibitors. The company was founded in 2003 and is headquartered in South San Francisco, California.
Is PTLA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 41.27
52 Week Low 15.68
Average Volume 22,783,430
200-Day Moving Average 26.2103
50-Day Moving Average 37.5842
20-Day Moving Average 38.193
10-Day Moving Average 38.757
Average True Range 1.2165
ADX 15.66
+DI 24.43
-DI: 15.56
Chandelier Exit (Long, 3 ATRs) 36.9805
Chandelier Exit (Short, 3 ATRs) 38.8695
Upper Bollinger Band 40.3825
Lower Bollinger Band 36.0035
Percent B (%b) 0.91
Bandwidth 0.114655